Streetbeat News

Stock Prices

MRNA

Moderna (NASDAQ:MRNA) has significantly outperformed the market with an average annual return of 42.13% over the past 5 years. An investment of $100 in MRNA stock 5 years ago would be worth $541.55 today. Moderna's market capitalization currently stands at $32.61 billion.

Portfolio Pulse from Benzinga Insights

December 18, 2023 | 4:30 pm

YUM

Yum Brands (NYSE:YUM) has seen a 3.23% increase in short interest since its last report, with 4.47 million shares sold short, representing 1.6% of its float. It would take about 3.59 days to cover all short positions. While an increase in short interest can indicate bearish sentiment, Yum Brands has less short interest compared to its peers' average of 9.23%. The rise in short interest doesn't necessarily predict a stock price drop.

Portfolio Pulse from Benzinga Insights

December 18, 2023 | 4:30 pm

TMO

Thermo Fisher Scientific (NYSE:TMO) has delivered an average annual return of 19.16% over the past 5 years, outperforming the market by 4.76% on an annualized basis. A $1000 investment in TMO 5 years ago would be worth $2,360.53 today. The company's market capitalization stands at $200.89 billion.

Portfolio Pulse from Benzinga Insights

December 18, 2023 | 4:30 pm

CB

Wells Fargo analyst Elyse Greenspan has downgraded Chubb (NYSE:CB) from Overweight to Equal-Weight and reduced the price target from $253 to $240.

Portfolio Pulse from Benzinga Newsdesk

December 18, 2023 | 4:30 pm

CKPT

Checkpoint Therapeutics' stock is trading lower following the FDA's issuance of a complete response letter for the biologic license application of cosibelimab, which was impacted by inspection findings at a third-party manufacturer.

Portfolio Pulse from Benzinga Newsdesk

December 18, 2023 | 4:29 pm

BMRA

Biomerica, Inc. has received FDA 510(k) clearance for its H. pylori test, Hp Detect ELISA, causing its stock to trade higher.

Portfolio Pulse from Benzinga Newsdesk

December 18, 2023 | 4:28 pm

TROX

Tronox Holdings' stock (TROX) is trading higher following an upgrade from BMO Capital, which changed its rating from Market Perform to Outperform and increased the price target from $11 to $18.

Portfolio Pulse from Benzinga Newsdesk

December 18, 2023 | 4:26 pm

NVO

A study has linked the brain impact of Ozempic, a diabetes medication, to potential benefits in heart disease. The findings suggest that the drug's effect on the brain could be contributing to its cardiovascular benefits. Ozempic is manufactured by Novo Nordisk (NVO).

Portfolio Pulse from Benzinga Newsdesk

December 18, 2023 | 4:24 pm

ZJYL

JinMed's stock price has declined following the announcement of a preliminary memorandum of understanding to potentially acquire a full or partial stake in Zhongjin Kanglu.

Portfolio Pulse from Benzinga Newsdesk

December 18, 2023 | 4:23 pm

VFC

V.F. Corp's stock is trading lower following the company's announcement of unauthorized access to its IT systems on December 13, which led to business disruptions and data theft.

Portfolio Pulse from Benzinga Newsdesk

December 18, 2023 | 4:22 pm